Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160312 | 0.93 | MAPT (0.48) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL3151043 | 0.92 | LMNA (0.49) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL3970658 | 0.84 | MAPT (0.46) | LMNAMAPTNPC1THRBTP53 | |
| SCHEMBL13451195 | 0.78 | SCD (0.46) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL3150199 | 0.77 | NPC1 (0.41) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL3159788 | 0.77 | NPC1 (0.42) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL3150420 | 0.76 | MAPT (0.50) | MAPTNPC1RAB9ATP53HRH3 | |
| SCHEMBL3972252 | 0.76 | MAPT (0.50) | LMNAMAPTNPC1THRBRAB9A | |
| SCHEMBL1744869 | 0.76 | KDM4E (0.54) | MAPTNPC1RAB9ATP53HRH3 | |
| SCHEMBL3184753 | 0.76 | NPC1 (0.59) | MAPTNPC1RAB9ATP53HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651615-B1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-1651615-B1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7294626-B2 | Piperazines | NOVO NORDISK A/S (DK) | 2007-11-13 | — | — | US | disclosed |
| US-7294626-B2 | Piperazines | NOVO NORDISK A/S (DK) | 2007-11-13 | — | — | US | disclosed |
| US-7294626-B2 | Piperazines | NOVO NORDISK A/S (DK) | 2007-11-13 | — | — | US | disclosed |
| US-20060173012-A1 | Novel piperazines | NOVO NORDISK A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1651615-A1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009976-A1 | PYRIDAZINYL- PIPERAZINES AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | NOVO NORDISK A/S (DK) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173012-A1 | Novel piperazines | HRH3, HRH2, HRH4 | LMNA 4299/4885MAPT 2598/4885NPC1 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.